SAR425899 was developed for the treatment of patients with T2D and obesity11–14 aiming to lower glucose at least similar to marketed GLP-1 agonists, but with superior weight loss over GLP-1 receptor mono-agonists. Here, GCG is linked to type 2 diabetes mellitus.